Recall of Pipeline Embolization Device and Alligator Retrieval Device

According to Department of Health, Therapeutic Goods Administration, this recall involved a device in Australia that was produced by Covidien Pty Ltd.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
  • Event ID
  • Event Risk Class
    Class I
  • Event Initiated Date
  • Event Country
  • Event Source
  • Event Source URL
  • Notes / Alerts
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Extra notes in the data
  • Reason
    Through internal testing, covidien identified certain lots of the pipeline embolization device and the alligator retrieval device that have the potential for the ptfe (polytetrafluoroethylene) coating on the delivery wire to delaminate and detach. there have been no patient injuries reported.
  • Action
    Covidien is requesting hospitals to discontinue use of the devices and segregate from other inventory. Covidien will arrange for the pick-up and return of the affected devices. This action has been closed-out on 10/02/2016.


  • Model / Serial
    Pipeline Embolization Device and Alligator Retrieval DevicePipeline Embolization DeviceProduct Code: FA-77350-14V07Lot Number: 9855265ARTG Number: 186413Alligator Retrieval DeviceProduct Code: FA-88810-30V03Lot Number: 9791385ARTG Number: 190843
  • Product Classification
  • Manufacturer


  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source